A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
Status:
Completed
Trial end date:
2021-05-17
Target enrollment:
Participant gender:
Summary
The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled
dose finding study is to assess the efficacy and safety of three different doses of LC350189
in subjects with hyperuricemia and a diagnosis of gout.